Scovella
Opinion
velagliflozin
MedicineVeterinaryOpinion
Italian is available via eTranslation, the European Commission's machine translation service.
Translate to Italian | Important information about machine translation
On 5 November 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the veterinary medicinal product 'Scovella 15 mg/ml oral solution', intended for non-food-producing horses. The applicant for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.
Scovella is a 'glucoside sodium-dependent glucose co-transporter 2' (SGLT-2) inhibitor medicinal product containing velagliflozin (ATCvet code QA10BK90) as the active substance. Inhibition of SGLT-2 decreases renal glucose reabsorption, which reduces blood glucose levels and thus allows for the control of hyperglycaemia.
The benefits of Scovella are the reduction of hyperinsulinaemia and reduction of associated risk of laminitis in horses with Equine Metabolic Syndrome not responsive to changes in husbandry and exercise regimen.
The most common side effects are elevated triglycerides, elevated liver enzymes, elevated cholesterol, lipaemia and elevated blood urea nitrogen (BUN).
Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Scovella and therefore recommends the granting of the marketing authorisation.
Note: Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.